These results strongly suggest that SKI can inhibit MCP-1 and CCR2 via the p38 MAPK and NFκB signaling pathways, thereby alleviating inflammation and mitigating kidney damage in diabetic nephropathy (Figure 8). This evidence concerns the gene CCL2 and diabetic kidney disease.